Roots Analysis has done a detailed study on Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030., covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 350+ page report, which features 140+ figures and 170+ tables, please visit this link
Key Market Insights
For more information, please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Cancer Immunotherapy
3.3. Fundamentals of Cancer Immunotherapy
3.4. Immune Checkpoint Modulators
3.5. First Generation Immune Checkpoint Modulators
3.6. Next Generation Immune Checkpoint Modulators
3.6.1. Types of Next Generation Immune Checkpoint Modulators
3.7. Challenges-related to Immune Checkpoint Modulation-based Therapy
3.8. Future Perspectives
4. CURRENT MARKET LANDSCAPE: CLINICAL AND PRECLINICAL MOLECULES
4.1. Chapter Overview
4.2. Next Generation Immune Checkpoint Inhibitors and Stimulators: Marketed and Development Pipeline
4.3. Next Generation Immune Checkpoint Inhibitors and Stimulators: Pipeline Analysis
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Target Immune Checkpoint
4.3.3. Analysis by Mechanism of Action
4.3.4. Analysis by Therapeutic Modality
4.3.5. Analysis by Route of Administration
4.3.6. Analysis by Target Disease Indication
4.3.7. Analysis by Therapeutic Area
4.3.8. Analysis by Type of Therapy
4.3.9. Funnel Representation: Analysis by Phase of Development, Mechanism of Action and Type of Therapy
4.4. Next Generation Immune Checkpoint Inhibitors and Stimulators: List of Drug Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size and Geographical Location
4.4.3. Leading Developer Companies: Analysis by Number of Pipeline Therapies
4.4.4. World Map Representation: Analysis by Geography
5. MARKET LANDSCAPE: THERAPIES TARGETING CD47
5.1. Chapter Overview
5.2. Next Generation Immune Checkpoint Inhibitors: Development Pipeline of CD47 Targeting Therapies
5.3. Next Generation Immune Checkpoint Inhibitors: Pipeline Analysis of CD47 Targeting Therapies
5.3.1. Analysis by Phase of Development
5.3.2. Analysis by Therapeutic Modality
5.3.3. Analysis by Route of Administration
5.3.4. Analysis by Target Disease Indication
5.3.5. Analysis by Type of Therapy
5.4. Next Generation Immune Checkpoint Inhibitors: List of Companies Developing CD47 Targeting Therapies
5.4.1. Analysis by Year of Establishment
5.4.2. Analysis by Company Size and Geographical Location
5.4.3. Leading Developers: Analysis by Number of Therapies
5.4.4. World Map Representation: Analysis by Geography
6. MARKET LANDSCAPE: THERAPIES TARGETING 4-1BB
6.1. Chapter Overview
6.2. Next Generation Immune Checkpoint Stimulators: Development Pipeline of 4-1BB Targeting Therapies
6.3. Next Generation Immune Checkpoint Stimulators: Pipeline Analysis of 4-1BB Targeting Therapies
6.3.1. Analysis by Phase of Development
6.3.2. Analysis by Therapeutic Modality
6.3.3. Analysis by Route of Administration
6.3.4. Analysis by Target Disease Indication
6.3.5. Analysis by Type of Therapy
6.4. Next Generation Immune Checkpoint Stimulators: List of Companies Developing 4-1BB Targeting Therapies
6.4.1. Analysis by Year of Establishment
6.4.2. Analysis by Company Size and Geographical Location
6.4.3. Leading Developers: Analysis by Number of Therapies
6.4.4. World Map Representation: Analysis by Geography
7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Next Generation Immune Checkpoint Inhibitors and Stimulators: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Phase
7.3.3. Analysis by Trial Recruitment Status
7.3.4. Analysis by Trial Registration Year and Number of Patients Enrolled
7.3.5. Analysis by Study Design
7.3.6. Analysis by Sponsor / Collaborator
7.3.7. Leading Industry Sponsors: Analysis by Number of Registered Trials
7.3.8. Word Cloud: Key Focus Areas
7.3.9. Analysis by Target Immune Checkpoint
7.3.10. Analysis by Target Therapeutic Area
7.3.11. Popular Interventions: Analysis by Number of Registered Trials
7.3.12. Geographical Analysis by Number of Registered Trials
7.3.13. Geographical Analysis by Trial Recruitment Status
7.3.14. Geographical Analysis by Number of Patients Enrolled
8. COMPANY PROFILES: NEXT GENERATION INHIBITORS AND STIMULATORS
8.1. Chapter Overview
8.2. Bristol-Myers Squibb
8.2.1. Company Overview
8.2.2. Financial Information
8.2.3. Next Generation Immune Checkpoint Therapeutics Portfolio
8.2.4. Recent Developments and Future Outlook
8.3. Eli Lilly
8.3.1. Company Overview
8.3.2. Financial Information
8.3.3. Next Generation Immune Checkpoint Therapeutics Portfolio
8.3.4. Recent Developments and Future Outlook
8.4. GlaxoSmithKline
8.4.1. Company Overview
8.4.2. Financial Information
8.4.3. Next Generation Immune Checkpoint Therapeutics Portfolio
8.4.4. Recent Developments and Future Outlook
8.4. Novartis
8.4.1. Company Overview
8.4.2. Financial Information
8.4.3. Next Generation Immune Checkpoint Therapeutics Portfolio
8.4.4. Recent Developments and Future Outlook
8.5. XOMA
8.5.1. Company Overview
8.5.2. Financial Information
8.5.3. Next Generation Immune Checkpoint Therapeutics Portfolio
8.5.4. Recent Developments and Future Outlook
9. ACADEMIC GRANTS ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Next Generation Immune Checkpoint Inhibitors and Stimulators: Analysis of Grants Awarded by the National Institutes of Health (NIH)
9.3.1. Analysis by Year of Grant Award
9.3.2. Analysis by Amount Awarded
9.3.3. Analysis by Administering Institute Center
9.3.4. Analysis by Funding Institute Center
9.3.5. Analysis by Support Period
9.3.6. Analysis by Funding Institute Center and Support Period
9.3.7. Analysis by Type of Grant Application
9.3.8. Analysis by Purpose of Grant Award
9.3.9. Anal
- Godzilla vs. Kong is already a box office sensation around the globe, but the movie just hit theaters in the United States, where the box office
- Get latest and updated exam material from mockdumps with passing guarantee in first try. We provide 24/7 customer support to our honorable students
- https://zenodo.org/communities/the-clouds-gather-full-movie-english-watch-online/
- Alexander plus the Awful, Terrible, No Exceptional, Really Terrible Working day will also be utilized with a lot of distinct pursuits to